Systemic Sclerosis & Related Disorders – Clinical Poster I
Friday, November 6, 2020
9:00 AM – 11:00 AM ET
Poster session.
Presentations:
9:00 AM – 11:00 AM ET
Increased Rates of Obstetric Complications Prior to Systemic Sclerosis Diagnosis Melody Chung, MD, MS – Johns Hopkins University
9:00 AM – 11:00 AM ET
Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials Elizabeth Volkmann, MD – University of California, Los Angeles
9:00 AM – 11:00 AM ET
Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease Nancy Wareing – McGovern Medical School at UTHealth
9:00 AM – 11:00 AM ET
A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Patients with Systemic Sclerosis Melody Chung, MD, MS – Johns Hopkins University
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Altered Iron Homeostasis and Pulmonary Haemodynamics in Systemic Sclerosis Associated Pulmonary Arterial Hypertension Alper Sari, MD – Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine
9:00 AM – 11:00 AM ET
Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial Masataka Kuwana, MD, PhD – Nippon Medical School Graduate School of Medicine
9:00 AM – 11:00 AM ET
Organ Specific Treatment Patterns of a Real-World, Electronic Health Record Cohort of Patients with Systemic Sclerosis Kyle Kidwell, MD – Vanderbilt University Medical Center
9:00 AM – 11:00 AM ET
Baseline Characteristics of Systemic Sclerosis (SSc) Patients with Restrictive Lung Disease in a Multi-Center United States Based Longitudinal Registry Flavia V. Castelino, MD – Massachusetts General Hospital
9:00 AM – 11:00 AM ET
Defining the Optimal Disease Duration of Early Diffuse Systemic Sclerosis for Clinical Trial Design Robyn T. Domsic, MD, MPH – University of Pittsburgh
9:00 AM – 11:00 AM ET
Prevalence and Survival of Systemic Sclerosis (SSc) and Associated Interstitial Lung Disease (ILD) in Ontario, Canada over 10 Years Janet Pope, MD, FRCPC, MPH – University of Western Ontario
9:00 AM – 11:00 AM ET
Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) Boyang Zheng, MD – McGill University
9:00 AM – 11:00 AM ET
Prevalence of a Diagnosis of Osteopenia/Osteoporosis Amongst Patients with Systemic Sclerosis and Identification of Associated Clinical Factors Diane Mar, MD – Stanford
9:00 AM – 11:00 AM ET
African Ancestry-Specific Variants Regulate TGFB3 Expression in Systemic Sclerosis Julia Hartman, BS – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
9:00 AM – 11:00 AM ET
Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial Dinesh Khanna, MD, MSc – University of Michigan
9:00 AM – 11:00 AM ET
Assessing Adherence to Screening of Systemic Sclerosis-Related Lung Disease Matthew J. Herrmann, MD, MS – HonorHealth
9:00 AM – 11:00 AM ET
Chest CT Ordering Practices at Expert Scleroderma Centers in the United States Elana J. Bernstein, MD – Columbia University
9:00 AM – 11:00 AM ET
A Heavy Burden of Calcinosis Reflects Cumulative Disease Damage in Scleroderma Carrie Richardson, MD, MHS – Rush University Medical Center
9:00 AM – 11:00 AM ET
Outcomes of Systemic Sclerosis Hospitalizations by Hospital Teaching Status: Analysis of the National Inpatient Sample Ehizogie Edigin – John H Stroger Jr. Hospital of Cook County
9:00 AM – 11:00 AM ET
Prevalence and Characteristics of Systemic Sclerosis Patients Fulfilling the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus Ronald Bass – Georgetown University School of Medicine
9:00 AM – 11:00 AM ET
Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis Francesco Del Galdo, MD, PhD – University of Leeds
